A federal appeals court has rejected class certification for third-party payers who claim Eli Lilly and Co. made misrepresentations about the effectiveness and safety of the drug Zyprexa.

The 2nd U.S. Circuit Court of Appeals reversed Eastern District of New York Judge Jack B. Weinstein, who in 2008 had certified a class of third-party payers, such as insurance providers, who claimed Lilly’s misrepresentations caused them to overpay for Zyprexa between June 20, 2001, to June 20, 2005.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]